References
- Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology115, 182–205 (1998).
- Clark M, Colombel FJ, Feagan BC et al. American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology133, 312–339 (2007).
- Rutgeerts P, Vermeire S, Assche GV. Biological therapies for inflammatory bowel diseases. Gastroenterology136, 1182–1197 (2009).
- Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am. J. Gastroenterol.104, 465–483 (2009).
- Peyrin-Biroulet L, Loftus Jr VE, Colombel FJ et al. The natural history of adult Crohn’s disease in population based cohorts. Am. J. Gastroenterol.105, 289–297 (2010).
- Travis LPS, Stange FE, Lemann M et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut55, 16–35 (2009).
- Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting α-4 integrin. Am. J. Gastroenterol.98, 2372–2382 (2003).
- Tysabri®, package insert. Biogen Idec Inc., Cambridge, MA, USA and Elan Pharmaceuticals, Inc, South San Francisco, CA, USA.
- Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348, 24–32 (2003).
- Sandborn WJ, Colombel FJ, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353, 1912–1925 (2005).
- Targan S, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology132, 1672–1683 (2007).
- MacDonald JK, McDonald JWD. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.1, CD006097 (2007).
- Moscandrew ME, Becker BD, Sandborn WJ et al. Natalizumab use in clinical practice in patients with moderate to severe Crohn’s disease. Gastroenterol.136(5 Suppl.1), A-653 (2009).
- Sands BE, Kozarek R, Spainhour J et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm. Bowel Dis.13(1), 2–11 (2007).
- Assche GV, Ranst MV, Sciot R et al. Progressive multifocal leucoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353, 362–368 (2005).
- Clifford DB, DeLuca A, Simpson DM et al. Natalizumab-associated progressive multifocal leucoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol.9, 438–446 (2010).
- Kleinschmidt-DeMasters BK, Tyler K. Progressive multifocal leucoencephalopathy complicating treatment with natalizumab and interferon β1a for multiple sclerosis. N. Engl. J. Med.353, 369–374 (2005).
- Yousry TA, Habil M, Major EO et al. Evaluation of patients treated with natalizumab for progressive multifocal leucoencephalopathy. N. Engl. J. Med.354, 924–933 (2006).
- Chen Y, Bord E, Tompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med.361, 1067–1074 (2009).
- Su C, Lichtenstein GR, Krok K et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology126, 1257–1269 (2004).
- D’Haens G, Baert F, Assche GV et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomized trial. Lancet371, 660–667 (2008).
- Behm BW, Bickston SJ. Humanized antibody to the α4β7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev.1, CD007571 (2009).
- Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med.352, 2499–2507 (2005).
- Feagan BG, Greenberg GR, Fedorak RN et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin. Gastroenterol. Hepatol.6(12), 1370–1377 (2008).